Mylan, Amgen score unanimous AdComm backing for Roche copycats; Alder raises $161M
→ Mylan and Amgen breezed through their advisory committee reviews on Thursday without any unexpected kickbacks for their two new knockoffs of a pair of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.